Castle biosciences (nasdaq:cstl) last released its quarterly earnings data on sunday, november 7th. Find the latest dividend yield (ttm) for castle biosciences, inc.
Is currently rated as a zacks rank 4 and we are expecting a below average return from the cstl shares relative to the market in the.
Castle biosciences stock zacks. Zacks investment research upgraded castle biosciences from a sell rating to a hold rating in a report on tuesday, october 26th. Castle biosciences has a one year low of $43.37 and a one year high of $107.69. 6 analysts are forecasting losses of $0.405 per share compared to losses of $0.230.
This compares to loss of $0.23 per share a year ago. Analysts anticipate castle biosciences, inc. The company reported ($0.47) earnings per share (eps) for the quarter, missing the zacks' consensus estimate of ($0.34) by ($0.13).
(cstl) came out with a quarterly loss of $0.47 per share versus the zacks consensus estimate of a loss of $0.35. Cstl | complete castle biosciences inc. Cstl investment & stock information.
(nasdaq:cstl) will announce quarterly sales of $23.43 million. This compares to loss of $0.08 per share a. Investors are always looking for stocks that are poised to beat at earnings season.
On november 9, castle biosciences releases figures for q3. (cstl) came out with a quarterly loss of $0.34 per share versus the zacks consensus estimate of a loss of $0.29. Zacks' proprietary data indicates that castle biosciences, inc.
Finally, svb leerink upped their target price on castle biosciences from $80.00 to $85.00 and gave the. Brokerages expect castle biosciences, inc. More zacks news for cstl.
The market expects castle biosciences, inc. Get the latest castle biosciences, inc. A positive reading for the zacks earnings esp has.
Canaccord genuity upped their target price on castle biosciences from $47.00 to $52.00 and gave the stock a buy rating in a report on friday, september 3rd. Mar 5, 2021 8:49am est. Dividend yield (ttm) is a widely used stock evaluation measure.
Ahead of this earnings release, the estimate revisions trend for castle biosciences, inc.
